NantKwest Profile

USD 0.15  3.95%

Sale by John Thomas of 13000 shares of NantKwest

NantKwest Inc insider trading alert for sale of common stock by John Thomas, the corporate stakeholder, on March 14, 2018. This event was filed by Nantkwest Inc with SEC on 2016-11-23. SEC Form: Changes in beneficial ownership [view details]   

NantKwest Summary

NantKwest Inc (NK) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 139 people. NantKwest is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Small-Cap' category with market capitalization of 326.56 M. NantKwest Inc is active under Healthcare sector as part of Biotechnology industry. This company has 79.46 M outstanding shares of which 4.26 M shares are now sold short in the market by investors with about 29.88 days to cover all shorted shares. NK reports about 128.15 M in cash with (48.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.62.
Check NantKwest Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Exposer

PriceHorizonTargetAbove OddsBelow Odds
 3.95 30 days 3.95  about 89.9% about 10.03%
Based on normal probability distribution, the odds of NantKwest to move above current price in 30 days from now is about 89.9%.

Top Holders

Selected NantKwest Inc Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

NantKwest Against Markets

Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
< 3% 
Equity ratings for NantKwest Inc are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
NantKwest, Inc., a clinical-stage immunotherapy biotechnology company, develops immunotherapeutic treatments for cancer, infectious diseases, and inflammatory diseases in the United States. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California. NantKwest operates under Biotechnology classification in USA and traded on NASDAQ. It employs 1 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameNantKwest Inc
President CEO, Board MemberBarry SimonView All
Thematic ClassificationPharmaceutical ProductsView All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock View All
RegionNorth America
Business Address3530 John Hopkins Court
CIK Number01326110.0
Contact Number858 633 0300
CurrencyUSD - US Dollar

Current Sentiment - NK

NantKwest Inc Investor Sentiment
Larger part of Macroaxis users are now bullish on NantKwest Inc. What is your trading attitude regarding investing in NantKwest Inc? Are you bullish or bearish?
98% Bullish
2% Bearish
Skip  Hide


NantKwest Analyst Recommendations
Target PriceAdvice# of Analysts
NantKwest Inc current and past analyst recommendations published by number of research institutions as well as average analyst consensus
NantKwest Analyst Advice  


Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  


NantKwest Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.45March 29, 2017
NantKwest Inc normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  


NantKwest Corporate Directors
Richard Kusserow Independent Director
Michael Blaszyk Independent Director
Frederick Driscoll Independent Director